Evidence map›Paper›PMID 37376042›Full record

ReviewPharmaceutics2023

Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review.

Cláudia Viegas, Ana B Patrício, João M Prata, Akhtar Nadhman, Pavan Kumar Chintamaneni, Pedro Fonte

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 203 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
203citing papers in PubMed, 2 pooled it
42.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

203 citing papers in PubMed, 2 syntheses or guidelines pooled it, 373 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Toxicity of nanostructures in drug delivery applications.Pharmaceutical science advances · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

143 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Cláudia ViegasCenter for Marine Sciences (CCMar), University of Algarve, Gambelas Campus, 8005-139 Faro, Portugal.ORCID 0000-0001-6668-2778
Ana B PatrícioiBB-Institute for Bioengineering and Biosciences, Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal.
João M PrataiBB-Institute for Bioengineering and Biosciences, Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal.ORCID 0000-0001-9063-7360
Akhtar NadhmanInstitute of Integrative Biosciences, CECOS University, Hayatabad, Peshawar 25000, Pakistan.
Pavan Kumar ChintamaneniDepartment of Pharmaceutics, GITAM School of Pharmacy, GITAM-Hyderabad Campus, Hyderabad 502329, Telangana, India.ORCID 0000-0002-8655-7680
Pedro FonteCenter for Marine Sciences (CCMar), University of Algarve, Gambelas Campus, 8005-139 Faro, Portugal.ORCID 0000-0002-1115-9282
University of Lisbon · PTCECOS University · PKGITAM University · IN

Funding

Fundação para a Ciência e Tecnologia 2020.08839.BDFundação para a Ciência e Tecnologia LA/P/0101/2020Fundação para a Ciência e Tecnologia LA/P/0140/2020Fundação para a Ciência e Tecnologia UIDB/04326/2020Fundação para a Ciência e Tecnologia UIDB/04565/2020Fundação para a Ciência e Tecnologia UIDP/04326/2020Fundação para a Ciência e Tecnologia UIDP/04565/2020
6 · The paper itself

Abstract

Solid-lipid nanoparticles and nanostructured lipid carriers are delivery systems for the delivery of drugs and other bioactives used in diagnosis, therapy, and treatment procedures. These nanocarriers may enhance the solubility and permeability of drugs, increase their bioavailability, and extend the residence time in the body, combining low toxicity with a targeted delivery. Nanostructured lipid carriers are the second generation of lipid nanoparticles differing from solid lipid nanoparticles in their composition matrix. The use of a liquid lipid together with a solid lipid in nanostructured lipid carrier allows it to load a higher amount of drug, enhance drug release properties, and increase its stability. Therefore, a direct comparison between solid lipid nanoparticles and nanostructured lipid carriers is needed. This review aims to describe solid lipid nanoparticles and nanostructured lipid carriers as drug delivery systems, comparing both, while systematically elucidating their production methodologies, physicochemical characterization, and in vitro and in vivo performance. In addition, the toxicity concerns of these systems are focused on.

Indexed as

lipid nanoparticlenanocarriernanoparticle characterizationnanoparticle productionNLCSLN

Identifiers

PMID37376042
PMCPMC10305282
OpenAlexW4378380780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.